AI Article Synopsis
- TGF-β/Smad signaling is a complex system that can both promote and inhibit tumor development, but its precise mechanisms are not fully understood.
- The study highlighted the TGF-β/Smad2/3 pathway as a key factor in the growth and spread of gastric cancer (GC) and identified the role of methyltransferase METTL3 in enhancing this pathway.
- The research revealed that METTL3 interacts with p-Smad3 to influence the transcription of genes involved in tumor progression, suggesting a new potential target for GC therapy.
Article Abstract
Transforming Growth factor-β (TGF-β)/Smad signaling is a complex regulatory network that both inhibits and promotes tumorigenesis. However, the mechanisms underlying the function of TGF-β/Smad signaling pathway remain to be fully elucidated. As a methyltransferase, METTL3 is closely related to tumor development, but the role of METTL3 in the proliferation and metastasis of TGF-β/Smad-activated gastric cancer (GC) is unclear. In this study, we identified TGF-β/Smad2/3 axis as an important carcinogenic pathway in GC, which significantly promoted the proliferation and metastasis of GC. Furthermore, we found that Smad3 mRNA could be modified by m6A, which was subsequently recognized and stabilized by IGF2BP2, thereby enhancing Smad3 protein expression and promoting the activation of TGF-β/Smad pathway. Importantly, we also found that METTL3 could combine with p-Smad3 to regulate the transcription of downstream target genes. Therefore, this study revealed a novel mechanism by which METTL3 synergistically regulates TGF-β/Smad2/3 signaling and provide a new potential therapeutic target for the treatment of GC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408465 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!